IGF1 and hypogonadism: Furthermore, specifically designed trials are needed to dissect the consequences of altered sex steroid levels (e.g., in hypogonadism) from those arising from increased (or decreased) FSH levels on similarly affected target organs, and to better clarify the impact on, for example, the GH/IGF-1 axis.